|
|
³¯Â¥ |
2010-12-02 |
|
|
Á¦¸ñ |
Pharma Koreana Korea Pharmaceutical News & Report |
|
|
³»¿ë |
Pharma Koreana May 2007 Vol.17 No.5
Contents REGULATORY AFFAIRS 3 The first cases of reduction in prices of patent-expired original drugs raise questions 3 Pharmacoeconomic evaluation to be carried out from July 6 Pharmaceutical firms weighing administrative litigation and patent suit regarding reduction in prices of their original drugs 7 Number of drugs on the reimbursement list total 17007 9 The US core demands accepted in the Korea-US FTA negotiations 10 Damages from the Korea-US FTA estimated at £Ü500 billion for pharmaceutical industry for five years 11 Multinational pharmaceutical firms expected to expand their investment in R&D 11 The number of clinical study approval records a 6.6-fold increase during the past six years 12 KFDA to make public the drug assessment and approval process 12 GMP assessment to be switched from formulation type to individual products 13 Clinical trials for eight therapeutic genes underway 14 KPA and multinational pharmaceutical firms to cooperate 15 Doctors' prescription of 881 high-priced drugs to be monitored 15 Criteria newly established for medical insurance based reimbursement for 23 anticancer agents 17 Clinical study in Japan fails to demonstrate Iressa's survival benefit 17 Nine tranquilizers to be covered by health insurance 17 Novartis Korea's Sebivo not to be covered by insurance 18 Labeling of 'tar dye addition' to become mandatory MARKET INFORMATION 19 Foreign-invested pharmaceutical firms occupy 29.75% of the market 23 Sales gap widening between top-ranking pharmaceutical firms and low-ranking pharmaceutical firms 23 Stockholder value-based management becoming important 25 Foreign-invested pharmaceutical firms have a cash-to-sales ratio of 7.02 percent on average 26 Hanmi's Amodipin ranks first in reimbursement claim 27 Decline in sales of Bacchus and Vita500 differently influences performance of their firms 30 Pfizer Korea reduces the price of Lipitor 31 Domestic pharmaceutical firms taking up vaccines from foreign-invested pharmaceutical firms 31 Original and generic drugs to contend intensely in antihypertensive market 32 LG Life Sciences has the highest R&D costs-to-sales ratio 33 Domestic pharmaceutical firms developing 124 new drugs 34 Twelve pharmaceutical wholesalers occupy 48.6 percent of the market 35 Pharmaceutical wholesalers perform well in 2006 37 Share of pharmacies in drug distribution increasing 38 Samyang seeking M&A with a local pharmaceutical firm 38 Successive launch of anti-osteoporotic agents with long term dosing expected 39 GSK Korea to launch anti-osteoporotic and cancer-targeting drugs 39 LG Life Sciences launches world's first sustained-release growth hormone 39 Janssen Korea's OTC drugs expected to be absorbed into J&J Korea 40 Korea Johnson and Chong Kun Dang increase prices of household insecticides ahead of summer 41 Consumer sentiment improves 42 Orthopedics clinics earn most 43 Korea to open FTA talks with EU in May 44 IMF expects Korean economy to grow 4.4% 44 Foreign patients in Cheju allowed to get 4-year stay REGULAR FEATURES 40 Sam-A makes a fresh start with its new name 40 Daewon launches Sanorex for the treatment of obesity 40 Development of new chemical drugs to benefit from various supports 41 Ilwha launches Aclaton a gastric prokinetic drug 41 Janssen Korea's Tylenol shows highest market share for two consecutive years 41 Yungjin launches HureGin Q10 containing red ginseng and Coenzyme Q10 PROFILES 46 Summary of Korean pharmaceutical manufacturers KOREA PATENT INFORMATION 49 Patents for blockbuster products close to successive expiration 49 Sewon Cellontech obtains a patent for a therapeutic cell for bone fracture healing 50 KFDA acquires a patent on natural substances for the treatment of narcotic addiction 50 List of unexamined patents published between March 11th 2007 and April 10th 2007 58 Abstracts for patents registered between March 11th 2007 and April 10th 2007 WORLDWIDE PATENT INFORMATION 74 Worldwide patent news REPORT 79 Import performance outlined in 2006 90 List of high-priced drugs in the second quarter of 2007
°ü·ÃURL : http://www.pharmakoreana.com
|
|
|